Inhibitor Therapeutics, Inc. (INTI)
USD 0.05
(-9.62%)
USD 0.05
(-9.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.66 Million USD | -0.37% |
| 2022 | 3.67 Million USD | -0.02% |
| 2021 | 3.67 Million USD | 5.37% |
| 2020 | 3.49 Million USD | 1.77% |
| 2019 | 3.43 Million USD | 185.77% |
| 2018 | 1.2 Million USD | 99.61% |
| 2017 | 601.48 Thousand USD | 95.2% |
| 2016 | 308.13 Thousand USD | -33.29% |
| 2015 | 461.88 Thousand USD | 15.21% |
| 2014 | 400.89 Thousand USD | -48.34% |
| 2013 | 776.05 Thousand USD | -27.42% |
| 2012 | 1.06 Million USD | -38.74% |
| 2011 | 1.74 Million USD | -69.63% |
| 2010 | 5.74 Million USD | -12.69% |
| 2009 | 6.58 Million USD | -7.38% |
| 2008 | 7.1 Million USD | -29.68% |
| 2007 | 10.1 Million USD | 131.08% |
| 2006 | 4.37 Million USD | -14.71% |
| 2005 | 5.12 Million USD | 1.7% |
| 2004 | 5.04 Million USD | 19.75% |
| 2003 | 4.2 Million USD | -6.07% |
| 2002 | 4.48 Million USD | -4.52% |
| 2001 | 4.69 Million USD | -6.01% |
| 2000 | 4.99 Million USD | 0.53% |
| 1999 | 4.96 Million USD | -2.59% |
| 1998 | 5.1 Million USD | 750.0% |
| 1997 | 600 Thousand USD | 50.0% |
| 1996 | 400 Thousand USD | 233.33% |
| 1995 | 120 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.03 Million USD | -3.81% |
| 2024 Q1 | 3.15 Million USD | -13.9% |
| 2023 Q2 | 3.04 Million USD | -1.12% |
| 2023 Q3 | 3.15 Million USD | 3.7% |
| 2023 Q4 | 3.66 Million USD | 16.12% |
| 2023 FY | 3.66 Million USD | -0.37% |
| 2023 Q1 | 3.07 Million USD | -16.32% |
| 2022 Q4 | 3.67 Million USD | -10.0% |
| 2022 Q3 | 4.08 Million USD | 3.88% |
| 2022 Q2 | 3.93 Million USD | 2.74% |
| 2022 FY | 3.67 Million USD | -0.02% |
| 2022 Q1 | 3.83 Million USD | 4.09% |
| 2021 FY | 3.67 Million USD | 5.37% |
| 2021 Q3 | 3.62 Million USD | -0.59% |
| 2021 Q4 | 3.67 Million USD | 1.38% |
| 2021 Q1 | 3.53 Million USD | 1.28% |
| 2021 Q2 | 3.65 Million USD | 3.24% |
| 2020 Q4 | 3.49 Million USD | 0.43% |
| 2020 Q3 | 3.47 Million USD | -0.29% |
| 2020 Q2 | 3.48 Million USD | 4.22% |
| 2020 Q1 | 3.34 Million USD | -2.48% |
| 2020 FY | 3.49 Million USD | 1.77% |
| 2019 Q2 | 3.3 Million USD | 81.1% |
| 2019 FY | 3.43 Million USD | 185.77% |
| 2019 Q4 | 3.43 Million USD | 2.15% |
| 2019 Q3 | 3.35 Million USD | 1.64% |
| 2019 Q1 | 1.82 Million USD | 51.99% |
| 2018 Q3 | 4.5 Million USD | 59.77% |
| 2018 Q1 | 441.16 Thousand USD | -26.66% |
| 2018 FY | 1.2 Million USD | 99.61% |
| 2018 Q4 | 1.2 Million USD | -73.38% |
| 2018 Q2 | 2.82 Million USD | 539.84% |
| 2017 Q3 | 252.2 Thousand USD | -25.73% |
| 2017 Q2 | 339.57 Thousand USD | -14.21% |
| 2017 Q1 | 395.8 Thousand USD | 28.45% |
| 2017 FY | 601.48 Thousand USD | 95.2% |
| 2017 Q4 | 601.48 Thousand USD | 138.49% |
| 2016 Q1 | 743.43 Thousand USD | 60.96% |
| 2016 Q2 | 618.07 Thousand USD | -16.86% |
| 2016 Q3 | 469.6 Thousand USD | -24.02% |
| 2016 Q4 | 308.13 Thousand USD | -34.38% |
| 2016 FY | 308.13 Thousand USD | -33.29% |
| 2015 Q2 | 412.69 Thousand USD | -27.42% |
| 2015 Q3 | 540.4 Thousand USD | 30.95% |
| 2015 FY | 461.88 Thousand USD | 15.21% |
| 2015 Q1 | 568.56 Thousand USD | 41.82% |
| 2015 Q4 | 461.88 Thousand USD | -14.53% |
| 2014 Q4 | 400.89 Thousand USD | -7.34% |
| 2014 FY | 400.89 Thousand USD | -48.34% |
| 2014 Q3 | 432.64 Thousand USD | -4.68% |
| 2014 Q2 | 453.87 Thousand USD | -53.34% |
| 2014 Q1 | 972.78 Thousand USD | 25.35% |
| 2013 Q1 | 1.07 Million USD | 0.77% |
| 2013 FY | 776.05 Thousand USD | -27.42% |
| 2013 Q4 | 776.05 Thousand USD | 40.9% |
| 2013 Q3 | 550.77 Thousand USD | 77.84% |
| 2013 Q2 | 309.7 Thousand USD | -71.26% |
| 2012 Q1 | 1.78 Million USD | 2.05% |
| 2012 Q2 | 1.79 Million USD | 1.05% |
| 2012 Q3 | 886.43 Thousand USD | -50.75% |
| 2012 Q4 | 1.06 Million USD | 20.62% |
| 2012 FY | 1.06 Million USD | -38.74% |
| 2011 Q4 | 1.74 Million USD | -55.88% |
| 2011 Q3 | 3.95 Million USD | -1.06% |
| 2011 FY | 1.74 Million USD | -69.63% |
| 2011 Q2 | 3.99 Million USD | -31.22% |
| 2011 Q1 | 5.81 Million USD | 1.16% |
| 2010 Q2 | 5.74 Million USD | -4.27% |
| 2010 Q4 | 5.74 Million USD | -3.08% |
| 2010 Q3 | 5.92 Million USD | 3.28% |
| 2010 Q1 | 5.99 Million USD | -8.88% |
| 2010 FY | 5.74 Million USD | -12.69% |
| 2009 Q2 | 6.99 Million USD | -3.17% |
| 2009 Q1 | 7.21 Million USD | 1.59% |
| 2009 FY | 6.58 Million USD | -7.38% |
| 2009 Q4 | 6.58 Million USD | -8.07% |
| 2009 Q3 | 7.15 Million USD | 2.41% |
| 2008 Q1 | 8.87 Million USD | -12.22% |
| 2008 Q3 | 6.89 Million USD | -19.37% |
| 2008 Q4 | 7.1 Million USD | 3.1% |
| 2008 FY | 7.1 Million USD | -29.68% |
| 2008 Q2 | 8.54 Million USD | -3.64% |
| 2007 Q3 | 9.79 Million USD | -11.83% |
| 2007 Q4 | 10.1 Million USD | 3.13% |
| 2007 Q2 | 11.11 Million USD | 126.31% |
| 2007 Q1 | 4.91 Million USD | 12.29% |
| 2007 FY | 10.1 Million USD | 131.08% |
| 2006 Q4 | 4.37 Million USD | -7.93% |
| 2006 FY | 4.37 Million USD | -14.71% |
| 2006 Q1 | 4.82 Million USD | -5.95% |
| 2006 Q2 | 5.1 Million USD | 5.82% |
| 2006 Q3 | 4.74 Million USD | -6.92% |
| 2005 Q4 | 5.12 Million USD | -2.85% |
| 2005 Q3 | 5.27 Million USD | -1.7% |
| 2005 Q1 | 5.5 Million USD | 9.26% |
| 2005 Q2 | 5.36 Million USD | -2.53% |
| 2005 FY | 5.12 Million USD | 1.7% |
| 2004 Q2 | 3.99 Million USD | -7.56% |
| 2004 Q1 | 4.32 Million USD | 2.69% |
| 2004 FY | 5.04 Million USD | 19.75% |
| 2004 Q4 | 5.04 Million USD | 29.98% |
| 2004 Q3 | 3.87 Million USD | -2.95% |
| 2003 Q4 | 4.2 Million USD | 0.2% |
| 2003 Q2 | 4.4 Million USD | -1.03% |
| 2003 FY | 4.2 Million USD | -6.07% |
| 2003 Q1 | 4.44 Million USD | -0.78% |
| 2003 Q3 | 4.2 Million USD | -4.54% |
| 2002 Q4 | 4.48 Million USD | 1.21% |
| 2002 Q1 | 4.58 Million USD | -2.32% |
| 2002 Q2 | 4.55 Million USD | -0.55% |
| 2002 Q3 | 4.42 Million USD | -2.89% |
| 2002 FY | 4.48 Million USD | -4.52% |
| 2001 Q3 | 4.64 Million USD | -5.3% |
| 2001 FY | 4.69 Million USD | -6.01% |
| 2001 Q1 | 4.96 Million USD | -0.61% |
| 2001 Q2 | 4.9 Million USD | -1.26% |
| 2001 Q4 | 4.69 Million USD | 1.13% |
| 2000 Q3 | 4.94 Million USD | 1.25% |
| 2000 Q4 | 4.99 Million USD | 1.09% |
| 2000 FY | 4.99 Million USD | 0.53% |
| 2000 Q1 | 5.08 Million USD | 2.44% |
| 2000 Q2 | 4.87 Million USD | -4.13% |
| 1999 Q1 | 4.8 Million USD | -5.88% |
| 1999 Q2 | 4.5 Million USD | -6.25% |
| 1999 FY | 4.96 Million USD | -2.59% |
| 1999 Q4 | 4.96 Million USD | 5.7% |
| 1999 Q3 | 4.7 Million USD | 4.44% |
| 1998 FY | 5.1 Million USD | 750.0% |
| 1998 Q1 | 4.6 Million USD | 666.67% |
| 1998 Q2 | 4.5 Million USD | -2.17% |
| 1998 Q3 | 4.5 Million USD | 0.0% |
| 1998 Q4 | 5.1 Million USD | 13.33% |
| 1997 Q2 | 580 Thousand USD | 0.0% |
| 1997 Q3 | 4 Million USD | 589.66% |
| 1997 Q4 | 600 Thousand USD | -85.0% |
| 1997 FY | 600 Thousand USD | 50.0% |
| 1996 FY | 400 Thousand USD | 233.33% |
| 1995 FY | 120 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.943% |
| Neon Bloom, Inc. | 1.22 Million USD | -198.901% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -353.164% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8100.206% |
| Qrons Inc. | 1.48 Million USD | -146.197% |
| Rebus Holdings, Inc. | 5.24 Million USD | 30.081% |
| Skye Bioscience, Inc. | 14.07 Million USD | 73.955% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.789% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13260.42% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.108% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1722.413% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 61.28% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.124% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 61.75% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -769.412% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.675% |
| Intellipharmaceutics International Inc. | 12 Million USD | 69.479% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 4.836% |
| Mesoblast Limited | 188.44 Million USD | 98.055% |
| Marizyme, Inc. | 26.67 Million USD | 86.26% |
| Genus plc | 485 Million USD | 99.244% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 37.268% |
| Pharming Group N.V. | 244.07 Million USD | 98.498% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -82.335% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -45.655% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 3.548% |
| ContraFect Corporation | 32.53 Million USD | 88.733% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -84.987% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 4.245% |
| IMV Inc. | 37.93 Million USD | 90.338% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 68.882% |
| MultiCell Technologies, Inc. | 1617.67 USD | -226470.561% |
| ONE Bio Corp. | 27.49 Million USD | 86.67% |
| Accustem Sciences Inc. | 1.07 Million USD | -239.606% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.266% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -73.288% |
| Q BioMed Inc. | 8.13 Million USD | 54.934% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.581% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 28.777% |
| Biomind Labs Inc. | 1.49 Million USD | -144.571% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.913% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 59.466% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.084% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -155.615% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2479.376% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 36.212% |
| GB Sciences, Inc. | 5.41 Million USD | 32.347% |
| Alpha Cognition Inc. | 7.16 Million USD | 48.845% |
| HST Global, Inc. | 593.59 Thousand USD | -517.454% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -191.072% |
| Halberd Corporation | 728.71 Thousand USD | -402.96% |
| Enzolytics Inc. | 365.26 Million USD | 98.997% |
| Agentix Corp. | 2.51 Million USD | -45.99% |
| Resverlogix Corp. | 67.39 Million USD | 94.562% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -336.989% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.176% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -113.837% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.189% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 69.208% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | 8.227% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13194.512% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.724% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1435.765% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 1.852% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -438.334% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -35.164% |
| Kadimastem Ltd | 3.5 Million USD | -4.574% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5376.197% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.708% |
| BioStem Technologies, Inc. | 15.9 Million USD | 76.955% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -688.718% |
| LadRx Corporation | 2.2 Million USD | -66.558% |
| Cell Source, Inc. | 15.8 Million USD | 76.813% |
| Regen BioPharma, Inc. | 5.45 Million USD | 32.843% |
| Regen BioPharma, Inc. | 5.45 Million USD | 32.843% |
| NovAccess Global Inc. | 7.86 Million USD | 53.374% |
| Affymax, Inc. | 8.87 Million USD | 58.684% |
| Itoco Inc. | 1.65 Million USD | -121.708% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -78.652% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 39.409% |
| Mobile Lads Corp. | 1.31 Million USD | -179.039% |
| CytoDyn Inc. | 127.89 Million USD | 97.134% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8668.545% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -133.99% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 66.817% |
| SYBLEU INC | 681.41 Thousand USD | -437.877% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 39.934% |
| International Stem Cell Corporation | 5.27 Million USD | 30.545% |
| Bioxytran, Inc. | 3.24 Million USD | -12.792% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -485.668% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 20.618% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.06% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.538% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -80.961% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 33.093% |
| Neutra Corp. | 973.52 Thousand USD | -276.482% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.368% |
| PureTech Health plc | 125.58 Million USD | 97.081% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 2.448% |
| IXICO plc | 1.9 Million USD | -92.874% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.146% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.453% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Cellectis S.A. | 249.36 Million USD | 98.53% |